Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic–pharmacodynamic analysis from the IELSG no. 20 trial

Markus Joerger(Kantonsspital St. Gallen), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Thomas Cerny(University of Bern), Franco Cavalli(Institute of Oncology Research), Emanuele Zucca(Ente Ospedaliero Cantonale), S. Krähenbühl(University Hospital of Basel), Michele Reni(San Raffaele University of Rome), J. Schellens(Utrecht University), A. D. R. Huitema(Slotervaartziekenhuis)
British Journal of Cancer
February 1, 2010
10.1038/sj.bjc.6605559
Cited by 85

Related Papers

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|677
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523